481 related articles for article (PubMed ID: 11888353)
1. Clinically significant interactions with drugs used in the treatment of tuberculosis.
Yew WW
Drug Saf; 2002; 25(2):111-33. PubMed ID: 11888353
[TBL] [Abstract][Full Text] [Related]
2. Clinically significant drug interactions with antituberculosis agents.
Grange JM; Winstanley PA; Davies PD
Drug Saf; 1994 Oct; 11(4):242-51. PubMed ID: 7848544
[TBL] [Abstract][Full Text] [Related]
3. The role of fluoroquinolones in tuberculosis today.
Berning SE
Drugs; 2001; 61(1):9-18. PubMed ID: 11217874
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
López-Cortés LF; Ruiz-Valderas R; Viciana P; Alarcón-González A; Gómez-Mateos J; León-Jimenez E; Sarasanacenta M; López-Pua Y; Pachón J
Clin Pharmacokinet; 2002; 41(9):681-90. PubMed ID: 12126459
[TBL] [Abstract][Full Text] [Related]
5. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2000 Mar; 49(9):185-9. PubMed ID: 11795500
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries.
Maartens G; Decloedt E; Cohen K
Antivir Ther; 2009; 14(8):1039-43. PubMed ID: 20032533
[TBL] [Abstract][Full Text] [Related]
7. Role of individual drugs in the chemotherapy of tuberculosis.
Mitchison DA
Int J Tuberc Lung Dis; 2000 Sep; 4(9):796-806. PubMed ID: 10985648
[TBL] [Abstract][Full Text] [Related]
8. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
9. Gatifloxacin in combination with rifampicin in a murine tuberculosis model.
Cynamon M; Sklaney MR; Shoen C
J Antimicrob Chemother; 2007 Aug; 60(2):429-32. PubMed ID: 17561504
[TBL] [Abstract][Full Text] [Related]
10. [Drug-resistant pulmonary tuberculosis at the penitentiaries].
Kononets AS
Probl Tuberk Bolezn Legk; 2008; (12):60-3. PubMed ID: 19227326
[TBL] [Abstract][Full Text] [Related]
11. Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis.
Rolla VC; da Silva Vieira MA; Pereira Pinto D; Lourenço MC; de Jesus Cda S; Gonçalves Morgado M; Ferreira Filho M; Werneck-Barroso E
Clin Drug Investig; 2006; 26(8):469-79. PubMed ID: 17163279
[TBL] [Abstract][Full Text] [Related]
12. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
[TBL] [Abstract][Full Text] [Related]
13. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings.
Semvua HH; Kibiki GS; Kisanga ER; Boeree MJ; Burger DM; Aarnoutse R
Ther Drug Monit; 2015 Feb; 37(1):22-32. PubMed ID: 24943062
[TBL] [Abstract][Full Text] [Related]
15. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1996 Oct; 45(42):921-5. PubMed ID: 8927017
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
[TBL] [Abstract][Full Text] [Related]
18. [Simultaneous resistance to rifampicin and isoniazid in patients with pulmonary tuberculosis].
Ouedraogo M; Ouedraogo SM; Diagbouga S; Coulibaly G; Achi V; Domoua K; N'Dathz M; Yapi A
Rev Mal Respir; 2000 Apr; 17(2):477-80. PubMed ID: 10859766
[TBL] [Abstract][Full Text] [Related]
19. Fluoroquinolones: a new treatment for tuberculosis?
Gillespie SH; Kennedy N
Int J Tuberc Lung Dis; 1998 Apr; 2(4):265-71. PubMed ID: 9559396
[TBL] [Abstract][Full Text] [Related]
20. Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin.
van Luin M; Brouwer AM; van der Ven A; de Lange W; van Schaik RH; Burger DM
AIDS; 2009 Mar; 23(6):742-4. PubMed ID: 19279450
[No Abstract] [Full Text] [Related]
[Next] [New Search]
